Should empagliflozin (Jardiance) be prescribed in a patient with an estimated glomerular filtration rate of 46 mL/min/1.73 m² and no proteinuria?

Yes, give Jardiance (empagliflozin) at GFR 46 mL/min/1.73 m², even without proteinuria.

The 2022 ADA/KDIGO consensus guidelines explicitly recommend SGLT2 inhibitors with proven kidney or cardiovascular benefit for patients with type 2 diabetes, CKD, and eGFR ≥20 mL/min/1.73 m²—regardless of albuminuria status 1. Your patient with a GFR of 46 falls squarely within this recommendation.

Why Proteinuria Doesn't Matter Here

The EMPA-KIDNEY trial fundamentally changed how we think about SGLT2 inhibitors in CKD. This landmark study enrolled patients with eGFR as low as 20 mL/min/1.73 m² and specifically included those without significant albuminuria (20% had uACR <30 mg/g) 2. The results were striking:

• Empagliflozin reduced kidney disease progression or cardiovascular death by 28% (HR 0.72) across all subgroups 2
• The benefit was consistent regardless of diabetes status or albuminuria level 3
• In fact, the relative benefit was actually larger in patients with lower albuminuria (86% reduction in chronic eGFR slope in those with uACR <30 mg/g versus 29% in those with uACR ≥2000 mg/g) 3

The key insight: Albuminuria alone should not determine whether to prescribe an SGLT2 inhibitor 3. Non-albuminuric diabetic kidney disease can exhibit "silent" eGFR loss, and empagliflozin slows this progression 4.

Dosing at GFR 46

Start with empagliflozin 10 mg once daily 1, 5. At this eGFR:

• The FDA label states empagliflozin is "not recommended" below 45 mL/min/1.73 m² for glycemic control specifically 5
• However, the 2022 ADA/KDIGO guidelines explicitly state this reflects outdated package insert information rather than current clinical guidance 1
• The guidelines recommend 10 mg daily for eGFR 30-44 (Stage 3b CKD), and your patient at 46 is just above this threshold 1
• Once initiated, continue empagliflozin even if eGFR falls below 45 or even below 20 mL/min/1.73 m² 1

What to Expect

The Initial "Dip"

Expect an acute eGFR decline of approximately 2 mL/min/1.73 m² (about 6% dip) in the first 2 months 3. This is:

• Hemodynamic and reversible, not kidney injury 1
• Not a reason to discontinue therapy 1
• Followed by a 50% reduction in the chronic rate of eGFR decline (from -2.75 to -1.37 mL/min/1.73 m²/year) 3

Real-world data confirms this pattern: in patients with Stage 3 CKD, only 21.6% experienced a >10% dip at 1 month, and eGFR increased by 2.75 mL/min/1.73 m² at 6 months overall 6.

Additional Benefits Beyond Kidney Protection

• Reduced cardiovascular death and heart failure hospitalization 2
• Modest weight loss (~2 kg) 6
• Systolic blood pressure reduction (~4-7 mmHg) 6, 7
• HbA1c reduction (~4 mmol/mol or 0.4%) 6

Safety Considerations

Volume Status

• Assess volume status before starting 5
• Consider reducing loop or thiazide diuretics if patient is at risk for hypovolemia 1
• Monitor blood pressure after initiation 1

Sick Day Protocol

Temporarily discontinue empagliflozin during:

• Prolonged fasting or surgery (stop 3-4 days before) 8
• Critical illness or acute medical stress 1
• Severe dehydration 1

This reduces the rare risk of euglycemic diabetic ketoacidosis (DKA), particularly if the patient requires insulin 1.

Genital Mycotic Infections

• Occur in ~6% of patients (vs 1% placebo) 1
• Higher risk in women 1
• Counsel on genital hygiene 1
• Most are easily treated; severe cases (Fournier gangrene) are rare 1

Monitoring

• Recheck eGFR at 2-4 weeks to document the expected dip
• Do not stop therapy based on this initial decline 1
• Continue monitoring eGFR every 3-6 months 9
• Monitor for volume depletion symptoms 1

Common Pitfall to Avoid

Do not withhold SGLT2 inhibitors based on absence of proteinuria. This outdated approach contradicts current evidence showing benefit across the entire spectrum of albuminuria 3. The 2024 BMJ guideline explicitly states that recommendations apply to patients with CKD defined by either decreased GFR (<60 mL/min/1.73 m²) or markers of kidney damage—not requiring both 10.

Bottom Line Algorithm

For your patient with diabetes, GFR 46, and no proteinuria:

1. Start empagliflozin 10 mg daily (cardiovascular and kidney protection indication, not just glycemic control) 1, 5
2. Assess volume status first; reduce diuretics if needed 1
3. Educate on sick day protocol (stop during illness/surgery) 1
4. Recheck eGFR in 2-4 weeks—expect 2-6% dip, continue therapy 3
5. Continue indefinitely, even if eGFR falls below 45 or 20 mL/min/1.73 m² 1
6. Monitor every 3-6 months for eGFR, volume status, and adverse effects 9

The absence of proteinuria is irrelevant to this decision. The evidence is clear: empagliflozin provides cardiorenal protection in this exact clinical scenario 3, 2.